AbbVie Inc. Files 8-K on Financials and Senior Notes
Ticker: ABBV · Form: 8-K · Filed: Oct 30, 2024 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, debt, sec-filing
Related Tickers: ABBV
TL;DR
AbbVie dropped an 8-K on Oct 30th detailing its financials and a bunch of senior notes due between 2027-2031.
AI Summary
On October 30, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes due in 2027, 2028, 2029, and 2031, with interest rates ranging from 0.750% to 2.625%. This report serves as an update on the company's financial standing and debt instruments.
Why It Matters
This filing provides investors with an update on AbbVie's financial health and its outstanding debt obligations, which are crucial for assessing the company's stability and future investment potential.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) that provides updates on operations and existing debt instruments, not indicating new or significant risks.
Key Numbers
- 0.750% — Senior Notes Interest Rate (Lowest interest rate on notes due 2027)
- 2.625% — Senior Notes Interest Rate (Highest interest rate on notes due 2028)
- 2027-2031 — Senior Notes Maturity Dates (Range of maturity dates for outstanding senior notes)
Key Players & Entities
- AbbVie Inc. (company) — Registrant
- October 30, 2024 (date) — Date of earliest event reported
- 0.750% (dollar_amount) — Interest rate on Senior Notes due 2027
- 2.625% (dollar_amount) — Interest rate on Senior Notes due 2028
- 2027 (date) — Maturity year for Senior Notes
- 2031 (date) — Maturity year for Senior Notes
FAQ
What is the purpose of this 8-K filing for AbbVie Inc.?
The 8-K filing on October 30, 2024, is to report on AbbVie Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
What specific financial instruments are mentioned in the filing?
The filing mentions several series of Senior Notes, including those due in 2027, 2028, 2029, and 2031, with varying interest rates.
What are the interest rates for the mentioned Senior Notes?
The interest rates range from 0.750% for notes due 2027, to 2.125% and 2.625% for notes due 2028, 2.125% for notes due 2029, and 1.250% for notes due 2031.
When was this report filed?
This 8-K report was filed as of October 30, 2024.
What is AbbVie Inc.'s fiscal year end?
AbbVie Inc.'s fiscal year ends on December 31.
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-10-30 07:43:14
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Filing Documents
- abbv-20241030.htm (8-K) — 39KB
- abbv-20240930xexhibit991.htm (EX-99.1) — 462KB
- abbvieimage1a53a.jpg (GRAPHIC) — 15KB
- 0001551152-24-000036.txt ( ) — 757KB
- abbv-20241030.xsd (EX-101.SCH) — 4KB
- abbv-20241030_def.xml (EX-101.DEF) — 19KB
- abbv-20241030_lab.xml (EX-101.LAB) — 35KB
- abbv-20241030_pre.xml (EX-101.PRE) — 20KB
- abbv-20241030_htm.xml (XML) — 8KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On October 30, 2024, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated October 30 , 2024 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 30, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer